Skip to Content

Intra-Cellular Therapies Inc ITCI

Morningstar Rating
$69.87 +0.12 (0.18%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ITCI is trading at a 1% premium.
Price
$67.71
Fair Value
$65.14
Uncertainty
Very High
1-Star Price
$854.29
5-Star Price
$74.72
Economic Moat
Jkbnh
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ITCI is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$69.75
Day Range
$69.8769.87
52-Week Range
$45.5276.06
Bid/Ask
$69.22 / $69.88
Market Cap
$6.76 Bil
Volume/Avg
3,969 / 795,138

Key Statistics

Price/Earnings (Normalized)
Price/Sales
14.46
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Growth
Total Number of Employees
561

Comparables

Valuation

Metric
ITCI
MRNS
SMMT
Price/Earnings (Normalized)
Price/Book Value
11.3628.8233.87
Price/Sales
14.4615.35
Price/Cash Flow
Price/Earnings
ITCI
MRNS
SMMT

Financial Strength

Metric
ITCI
MRNS
SMMT
Quick Ratio
4.953.799.17
Current Ratio
5.414.079.30
Interest Coverage
−7.94−36.99
Quick Ratio
ITCI
MRNS
SMMT

Profitability

Metric
ITCI
MRNS
SMMT
Return on Assets (Normalized)
−13.47%−59.45%−25.32%
Return on Equity (Normalized)
−15.88%−195.80%−71.75%
Return on Invested Capital (Normalized)
−17.96%−84.00%−24.62%
Return on Assets
ITCI
MRNS
SMMT
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ZTS
Zoetis Inc Class AVxfkjyybkJpcvw$77.2 Bil
MKKGY
Merck KGaA ADRThzwykdnqqFvzfz$75.4 Bil
HLN
Haleon PLC ADRGqmqnlnjmCzqlg$38.1 Bil
TEVA
Teva Pharmaceutical Industries Ltd ADRGbmgnlwyXxzc$16.0 Bil
VTRS
Viatris IncDxdvlfwfLcch$14.0 Bil
RDY
Dr Reddy's Laboratories Ltd ADRYqlqfhjVdy$12.1 Bil
CTLT
Catalent IncBfnzjtgfgXcjvfjn$10.2 Bil
PRGO
Perrigo Co PLCHgjjfnkyVqwq$4.3 Bil
CURLF
Curaleaf Holdings IncDbxscbsxRqzm$4.0 Bil
PBH
Prestige Consumer Healthcare IncZhgxmyqbMzcmz$3.6 Bil

Sponsor Center